CareLit · DOI-Nachweis · Zeitschrift für Gastroenterologie
Pro-apoptotic and anti-proliferative mechanisms of the kinase inhibitor tivantinib (ARQ 197)
DOI 10.1055/s-0033-1351191
Bibliografische Angaben
Nachweis in CareLit
Autor:innenEN De Toni, S Lu, A Rizzani, F Kolligs, E Gallmeier, B Göke, AL Gerbes
ZeitschriftZeitschrift für Gastroenterologie
Ausgabe09/2013
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Purpose: Tivantinib is a c-MET inhibitor which demonstrated clinical benefit as a second line treatment of hepatocellular carcinoma (HCC). Since its efficacy was predicted by elevated expression of c-MET in a phase 2 randomized trial, a phase 3 trial in patients selected according to c-MET expression has been initiated. Yet, the mechanisms of action of this new drug and its dependency of its efficacy on c-MET are un…
Zitieren
Zitierempfehlung
EN De Toni, S Lu, A Rizzani, F Kolligs, E Gallmeier, B Göke, AL Gerbes (2013) Pro-apoptotic and anti-proliferative mechanisms of the kinase inhibitor tivantinib (ARQ 197). Zeitschrift für Gastroenterologie (09). https://doi.org/10.1055/s-0033-1351191
Mit CareLit weiterarbeiten